The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: A bio-CORAL study

Journal of Clinical Oncology

Volumn 29, Issue 31, 2011, Pages 4079-4087

  Thieblemont, Catherine ^a,b,c   Briere, Josette ^a,b,c   Mounier, Nicolas ^c,d   Voelker, Hans Ullrich ^h   Cuccuini, Wendy ^a   Hirchaud, Edouard ^e   Rosenwald, Andreas ^h   Jack, Andrew ^j   Sundstrom, Christer ^k   Cogliatti, Sergio ^l   Trougouboff, Philippe ^m   Boudova, Ludmila ⁿ   Ysebaert, Loic ^f   Soulier, Jean ^a   Chevalier, Catherine ^e   Bron, Dominique ^o   Schmitz, Norbert ⁱ   Gaulard, Philippe ^c,g   Houlgatte, Remi ^e   Gisselbrecht, Christian ^c  

^a SAINT LOUIS HOSPITAL   (France)

^b INSERM   (France)

^c Groupe d'Etude des Lymphomes de l'Adulte   (France)

^d CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^e UNIVERSITÉ DE NANTES   (France)

^f CHU PURPAN   (France)

^g HENRI MONDOR HOSPITAL   (France)

^h UNIVERSITY OF WÜRZBURG   (Germany)

ⁱ DEPARTMENT OF CARDIOLOGY   (Germany)

^j UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^k UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^l University College London Hospital ^*

^m HAEMEK MEDICAL CENTER   (Israel)

ⁿ CHARLES UNIVERSITY   (Czech Republic)

^o JULES BORDET INSTITUTE   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; IFOSFAMIDE; INTERFERON REGULATORY FACTOR 4; MYC PROTEIN; PROTEIN BCL 2; PROTEIN BCL 6; RITUXIMAB;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CLASSIFICATION; CANCER RELAPSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG EXPOSURE; DRUG MEGADOSE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE EXPRESSION PROFILING; GENE REARRANGEMENT; GERMINAL CENTER; HUMAN; HUMAN TISSUE; IMMUNOCHEMISTRY; IMMUNOPHENOTYPING; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; SALVAGE THERAPY; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CISPLATIN; CYTARABINE; DEXAMETHASONE; DISEASE-FREE SURVIVAL; ETOPOSIDE; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GERMINAL CENTER; HUMANS; IFOSFAMIDE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MICROARRAY ANALYSIS; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; MULTIVARIATE ANALYSIS; NEOPLASM PROTEINS; NEOPLASM, RESIDUAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; RISK FACTORS; SALVAGE THERAPY; TUMOR MARKERS, BIOLOGICAL;

EID: 80755143466     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.35.4423     Document Type: Article

References (41)

1. Swerdlow S, Campo E, Harris N, et al.: WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. Lyon, France, IARC Press, 2008
2. Percy C, O'Conor G, Ries LG, et al.: Non-Hodgkin's lymphomas: Application of the International Classification of Diseases for Oncology (ICD-O) to the working formulation. Cancer 54:1435-1438, 1984 (Pubitemid 14003548)
3. Alizadeh AA, Eisen MB, Davis RE, et al.: Distinct types of diffuse large B cell lymphoma identified by gene expression profiling. Nature 403: 503-511, 2000 (Pubitemid 30082188)
4. Rosenwald A, Wright G, Chan WC, et al.: The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346:1937-1947, 2002 (Pubitemid 34651353)
5. Rosenwald A, Wright G, Leroy K, et al.: Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 198:851-862, 2003 (Pubitemid 37152922)
6. Davis RE, Ngo VN, Lenz G, et al.: Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 463:88-92, 2010
7. Lam LT, Davis RE, Ngo VN, et al.: Compensatory IKKalpha activation of classical NF-kappaB signaling during IKKbeta inhibition identified by an RNA interference sensitization screen. Proc Natl Acad Sci U S A 105:20798-20803, 2008
8. Lenz G, Davis RE, Ngo VN, et al.: Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 319:1676-1679, 2008 (Pubitemid 351432507)
9. Lenz G, Nagel I, Siebert R, et al.: Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma. J Exp Med 204:633-643, 2007 (Pubitemid 46457085)
10. Raharijaona M, Le Pennec S, Poirier J, et al.: PGC-1-related coactivator modulates mitochondrial-nuclear crosstalk through endogenous nitric oxide in a cellular model of oncocytic thyroid tumours. PLoS One 4:e7964, 2009
11. Lenz G, Wright G, Dave SS, et al.: Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 359:2313-2323, 2008
12. Barrans SL, Carter I, Owen RG, et al.: Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood 99:1136-1143, 2002 (Pubitemid 34547064)
13. Copie-Bergman C, Gaulard P, Leroy K, et al.: Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: A GELA study. J Clin Oncol 27:5573-5579, 2009
14. Hans CP, Weisenburger DD, Greiner TC, et al.: Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103:275-282, 2004 (Pubitemid 38029949)
15. Muris JJ, Meijer CJ, Vos W, et al.: Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma. J Pathol 208:714-723, 2006
16. Choi WW, Weisenburger DD, Greiner TC, et al.: A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res 15:5494-5502, 2009
17. Meyer PN, Fu K, Greiner TC, et al.: Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol 29:200-207, 2011
18. Sanchez E, Chacon I, Plaza MM, et al.: Clinical outcome in diffuse large B-cell lymphoma is dependent on the relationship between different cell-cycle regulator proteins. J Clin Oncol 16:1931-1939, 1998 (Pubitemid 28234743)
19. Mounier N, Briere J, Gisselbrecht C, et al.: Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 101:4279-4284, 2003 (Pubitemid 36857789)
20. Wilson WH, Dunleavy K, Pittaluga S, et al.: Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol 26:2717-2724, 2008
21. Banham AH, Connors JM, Brown PJ, et al.: Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma. Clin Cancer Res 11:1065-1072, 2005 (Pubitemid 40175755)
22. Brown PJ, Ashe SL, Leich E, et al.: Potentially oncogenic B-cell activation-induced smaller isoforms of FOXP1 are highly expressed in the activated B cell-like subtype of DLBCL. Blood 111:2816-2824, 2008
23. van Imhoff GW, Boerma EJ, van der Holt B, et al.: Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma. J Clin Oncol 24:4135-4142, 2006
24. Nyman H, Jerkeman M, Karjalainen-Lindsberg ML, et al.: Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP. Mod Pathol 22:1094-1101, 2009
25. Ott G, Ziepert M, Klapper W, et al.: Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL. Blood 116:4916-4925, 2010
26. Jais JP, Haioun C, Molina TJ, et al.: The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab. Leukemia 22:1917-1924, 2008
27. Gisselbrecht C, Glass B, Mounier N, et al.: Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 28:4184-4190, 2010
28. Haralambieva E, Kleiverda K, Mason DY, et al.: Detection of three common translocation breakpoints in non-Hodgkin's lymphomas by fluorescence in situ hybridization on routine paraffin-embedded tissue sections. J Pathol 198:163-170, 2002 (Pubitemid 35243874)
29. Kaplan E, Meier P: Non parametric estimation from incomplete observations. J Am Stat Assoc 153:457-481, 1958
30. Cox D: Regression model and life tables. J R Stat Soc B 34:187-220, 1972
31. Auffray C, Behar G, Bois F, et al.: IMAGE: Molecular integration of the analysis of the human genome and its expression [in French]. C R Acad Sci III 318:263-272, 1995
32. Baron D, Bihouee A, Teusan R, et al.: MADGene: Retrieval and processing of gene identifier lists for the analysis of heterogeneous microarray datasets. BMC Genomics 12:113, 2011
33. Dunleavy K, Little RF, Pittaluga S, et al.: The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SCEPOCH-RR) in HIV-associated diffuse large B-cell lymphoma. Blood 115:3017-3024, 2010
34. Dunleavy K, Pittaluga S, Czuczman MS, et al.: Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood 113:6069-6076, 2009
35. Chadburn A, Chiu A, Lee JY, et al.: Immunophenotypic analysis of AIDS-related diffuse large B-cell lymphoma and clinical implications in patients from AIDS Malignancies Consortium clinical trials 010 and 034. J Clin Oncol 27:5039-5048, 2009
36. Dunleavy K, Wilson WH: Role of molecular subtype in predicting outcome of AIDS-related diffuse large B-cell lymphoma. J Clin Oncol 28:e260; author reply e261-e262, 2010
37. de Jong D, Rosenwald A, Chhanabhai M, et al.: Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: Validation of tissue microarray as a prerequisite for broad clinical applications-A study from the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol 25:805-812, 2007 (Pubitemid 350002880)
38. de Jong D, Xie W, Rosenwald A, et al.: Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: Validation of tissue microarray as a prerequisite for broad clinical applications - A study from the Lunenburg Lymphoma Biomarker Consortium. J Clin Pathol 62:128-138, 2009
39. Ranuncolo SM, Wang L, Polo JM, et al.: BCL6-mediated attenuation of DNA damage sensing triggers growth arrest and senescence through a p53-dependent pathway in a cell context-dependent manner. J Biol Chem 283:22565-22572, 2008
40. Davis RE, Brown KD, Siebenlist U, et al.: Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 194:1861-1874, 2001 (Pubitemid 34028664)
41. Ngo VN, Davis RE, Lamy L, et al.: A loss-of-function RNA interference screen for molecular targets in cancer. Nature 441:106-110, 2006